Strength: 60 mg

Indications:

This drug product is indicated for the treatment of HCV Genotypes 1, 2, 3 and 6 infections in naive adult patients or patients previously treated with interferons as used in combination with sofosbuvir, complicated by compensatory cirrhosis or not.

Dosage and Administration:

Orally take 60 mg with or without meals once a day for 12 consecutive weeks.

Orally take sofosbuvir 400 mg with or without meals concomitantly once a day for 12 consecutive weeks.

Pharmacology:

Coblopasvir hydrochloride is an inhibitor of HCV NS5A replication complex. NS5A is a phosphate protein that can interact with a variety of host cell proteins and exert functions in the replication and assembly stages of the HCV life cycle. Studies have shown that NS5A may interact with other HCV proteins or host cell factors to play its role. Coblopasvir hydrochloride has a strong inhibitory effect on HCV genotypes 1a, 1b, 2a, 3a, 4a, 5a and 6a.

Storage:

Store in the original carton not higher than 30°C.

Package:

Pack in aluminum-plastic blisters. 7 capsules/blister ×1 blister/box; 7 capsules/blister ×2 blisters/box; 7 capsules/plate ×3 blisters/box; 7 capsules/blister ×4 blisters/box; 7 capsules/blister ×8 blisters/box; 7 capsules/blister ×12 blisters/box; 10 capsules/blister ×1 blister /box; 10 capsules/blister ×2 blisters /box; 10 capsules/blister ×3 blisters /box;

Shelf life:

24 months